{"nctId":"NCT00006392","briefTitle":"S0000 Selenium and Vitamin E in Preventing Prostate Cancer","startDateStruct":{"date":"2001-07"},"conditions":["Prostate Cancer"],"count":35533,"armGroups":[{"label":"Vitamin E + selenium placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Vitamin E","Other: selenium placebo"]},{"label":"Selenium + vitamin E placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Selenium","Other: Vitamin E placebo"]},{"label":"Vitamin E + selenium","type":"EXPERIMENTAL","interventionNames":["Drug: Vitamin E","Drug: Selenium"]},{"label":"Vitamin E placebo + selenium placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Vitamin E placebo","Other: selenium placebo"]}],"interventions":[{"name":"Vitamin E","otherNames":["alpha tocopherol"]},{"name":"Selenium","otherNames":["L-selenomethionine"]},{"name":"Vitamin E placebo","otherNames":["placebo"]},{"name":"selenium placebo","otherNames":["placebo"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Healthy male volunteers\n* Digital rectal examination (DRE) deemed not suspicious for prostate cancer performed within 364 days prior to study entry\n\n  * Participants with a suspicious DRE are ineligible even if a recent or subsequent biopsy is negative for cancer\n* Total prostate-specific antigen ≤ 4.0 ng/mL within 364 days prior to study entry\n* No prior prostate cancer or high-grade (grade 2-3) prostatic intraepithelial neoplasia\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* See Disease Characteristics\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nCardiovascular:\n\n* Systolic blood pressure \\< 160 mm Hg\n* Diastolic blood pressure \\< 90 mm Hg\n* No history of hemorrhagic stroke\n\nOther:\n\n* No malignancies within the past 5 years except basal cell or squamous cell skin cancer\n* No uncontrolled medical illness\n* No retinitis pigmentosa\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* At least 7 years since prior randomization to SWOG-9217, with completion of end-of-study biopsy requirement\n* No additional concurrent selenium or vitamin E (contained in individual supplements, antioxidant mix, or multivitamin)\n* Concurrent multivitamins allowed (supplied on study)\n* No concurrent anticoagulation therapy (e.g., warfarin)\n* Concurrent prophylactic aspirin (average daily dose no greater than 175 mg/day) allowed\n\n  * Concurrent daily aspirin dose ≤ 81 mg for participants receiving clopidogrel\n* Concurrent anti-hypertension medication allowed\n* No concurrent participation in another study involving a medical, surgical, nutritional, or life-style intervention (unless no longer receiving the intervention and are in the follow-up phase only)","healthyVolunteers":true,"sex":"MALE","minimumAge":"50 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Prostate Cancer","description":"Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"473","spread":null},{"groupId":"OG001","value":"432","spread":null},{"groupId":"OG002","value":"437","spread":null},{"groupId":"OG003","value":"416","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Lung Cancer","description":"Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Colorectal Cancer","description":"Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Diagnosis of Cancer","description":"Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"856","spread":null},{"groupId":"OG001","value":"837","spread":null},{"groupId":"OG002","value":"846","spread":null},{"groupId":"OG003","value":"824","spread":null}]}]}]},{"type":"SECONDARY","title":"Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival","description":"Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. Other cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"358","spread":null},{"groupId":"OG001","value":"378","spread":null},{"groupId":"OG002","value":"359","spread":null},{"groupId":"OG003","value":"382","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"128","spread":null},{"groupId":"OG002","value":"117","spread":null},{"groupId":"OG003","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Cardiovascular Events","description":"Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Cardiovascular events are based on self-report and are not confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1034","spread":null},{"groupId":"OG001","value":"1080","spread":null},{"groupId":"OG002","value":"1041","spread":null},{"groupId":"OG003","value":"1050","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":96,"n":8752},"commonTop":["Nail changes","Fatigue/malaise/lethargy","Dermatitis","Cardiac ischemia/infarction","Halitosis"]}}}